CytosorbentsvsJohnson & Johnson

CTSO and JNJ stock compared: price, dividend, valuation and results, from SEC filings.

CTSO

Cytosorbents Corporation

$4.52

Value –

-0.41%
CTSO's page

Over the last year, with dividends, CTSO moved -63.3% and JNJ +47.5%. Dividend yield: CTSO none, JNJ 1.89%.

At a glance

The main figures of both. A bar only shows which number is larger, not which is better.

  • Market value

    CTSO–

    JNJ$672B

  • Revenue, 12 months

    CTSO$37M

    JNJ$99.3B

    JNJ is 2,669 times CTSO

  • Net income, 12 months

    CTSO-$18M

    JNJ$16.1B

  • Operating margin

    CTSO-34.7%

    JNJ–

  • ROIC

    CTSO-45.0%

    JNJ12.4%

    57.3 points apart

  • P/E

    CTSO–

    JNJ41.7

  • Dividend yield

    CTSO0.0%

    JNJ1.9%

    1.9 points apart

  • 5-year return

    CTSO-96.0%

    JNJ+98.6%

    194.6 points apart

A fainter bar means a negative number. The 5-year return includes dividends.

The price over time

Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.

CTSO-96.0%

JNJ+98.6%

010020020222023202420252026
Returns by period
PeriodCTSOWith dividendsJNJWith dividends
1 year since November 14, 2025-63.3%Price -63.3%+47.5%Price +44.2%
3 years since November 16, 2023-78.0%-39.6% a yearPrice -78.0%+105.0%+27.0% a yearPrice +88.2%
5 years since November 15, 2021-96.0%-47.6% a yearPrice -96.0%+98.6%+14.7% a yearPrice +72.8%
10 years since November 17, 2016-95.5%-26.6% a yearPrice -95.5%+218.0%+12.3% a yearPrice +142.4%

Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.

Every figure

As on each company's page. A description, not a recommendation: no one figure says which is better.

CTSOCytosorbentsJNJJohnson & Johnson

Valuation

CTSOJNJ
Valuation
Price$4.52$278.70
Market value–$672B
Enterprise value (EV)–$699B
P/E–41.7
P/E, 5-year median–21.9
P/B–8.2
EV/EBIT–39.4
Free cash flow yield–3.1%

Results and growth

CTSOJNJ
Results and growth
Revenue, 12 months$37M$99.3B
Net income, 12 months-$18M$16.1B
Free cash flow, 12 months-$9.3M$20.6B
Earnings per share, 12 months-$0.29$6.59
Revenue growth, year on year4.1%6.1%
Revenue growth a year, past-2.0%over 5 years+2.7%over 5 years
EPS growth a year, past–+14.9%over 5 years

Margins and returns on capital

CTSOJNJ
Margins and returns on capital
Gross margin71.6%67.6%
Operating margin-34.7%–
Net margin-48.9%16.2%
ROIC-45.0%12.4%
ROE-325.8%19.7%

Balance sheet

CTSOJNJ
Balance sheet
Cash$4.4M$17.2B
Total debt$29M$44.7B
Net debt / EBITDA–1.1
Interest cover–18.0×

Dividends and buybacks

CTSOJNJ
Dividends and buybacks
Dividend yield–1.9%
Dividend per share, 12 months–$5.28
Dividend growth a year, past–+5.3%over 5 years
Buyback yield–0.9%
Shareholder yield–2.8%

Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.

Questions: CTSO or JNJ

Didn't find what you were looking for?

Ask us
How did CTSO and JNJ stock do over the last 10 years?

Since November 17, 2016, CTSO's price moved -95.5% and JNJ's +142.4%. With dividends: CTSO -95.5% (-26.6% a year), JNJ +218.0% (+12.3% a year). Past returns do not predict future ones.

Which pays the higher dividend, CTSO or JNJ?

The dividend yield at today's price is none for Cytosorbents and 1.89% for Johnson & Johnson. Over the last twelve months they paid – and $5.28 per share.

Which has the higher profit margins, Cytosorbents or Johnson & Johnson?

Over the last twelve months, the net margin was -48.9% for Cytosorbents and 16.2% for Johnson & Johnson, and the operating margin -34.7% and –. Revenue was $37M and $99.3B.

Which is the better investment, Cytosorbents or Johnson & Johnson?

The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.

Other comparisons

With each of the two, and with the largest in its sector.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

Descriptive data from SEC filings and market prices.